Literature DB >> 21249357

Pre-operative serum C-reactive protein as independent prognostic factor for survival but not infection in patients with high-grade osteosarcoma.

Philipp T Funovics1, Gundula Edelhauser, Martin A Funovics, Christoph Laux, Dominik Berzaczy, Bernd Kubista, Rainer I Kotz, Martin Dominkus.   

Abstract

PURPOSE: The purpose of this study was to investigate (a) whether pre-operative serum CRP is a predictor of survival in patients with high-grade osteosarcoma, (b) whether post-operative infection is a predictor of survival in these patients and (c) whether CRP is a predictor of post-operative infection, and especially deep prosthetic infection.
METHODS: In this retrospective single-centre study, pre-operative serum CRP levels in 79 patients (37 females, 42 males; average age, 18 years; mean follow-up, 46 months) undergoing resection of an osteosarcoma were correlated with clinical data and survival.
RESULTS: The mean pre-operative serum CRP level of all 79 patients was 0.53 mg/dl (SD, 1.27 mg/dl). Patients dying of their underlying disease had significantly higher CRP levels compared to patients surviving throughout the follow-up period (1.09 mg/dl ± 2.02 mg/dl versus 0.32 mg/dl ± 0.75 mg/dl, respectively; p = 0.015). CRP levels were significantly correlated with survival (Pearson's correlation coefficient = -0.25; p = 0.026) and histological subtype (Pearson's correlation coefficient = -0.42; p < 0.001), but not with sex, age, histological response, tumour size or metastatic disease. In uni- and multivariate survival analysis, age, response to chemotherapy and serum CRP were associated with disease-specific survival. Patients with a CRP level over 1 mg/dl had a significantly lower disease-specific five-year survival of 36.7% compared to 73.8% in patients with normal CRP values (p = 0.020). Infection was not correlated with disease-specific survival. Pre-operative serum CRP levels were not correlated with post-operative infection or deep prosthetic infection.
CONCLUSIONS: Pre-operative serum CRP seems to be an independent predictor of survival in patients with high-grade osteosarcoma. Further studies are needed to confirm these results on a large-scale basis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21249357      PMCID: PMC3174301          DOI: 10.1007/s00264-011-1208-8

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  35 in total

1.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

2.  Osteogenic sarcoma. A study of six hundred cases.

Authors:  D C Dahlin; M B Coventry
Journal:  J Bone Joint Surg Am       Date:  1967-01       Impact factor: 5.284

3.  [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors].

Authors:  M Salzer-Kuntschik; G Brand; G Delling
Journal:  Pathologe       Date:  1983-05       Impact factor: 1.011

4.  Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma.

Authors:  T Nozoe; H Saeki; K Sugimachi
Journal:  Am J Surg       Date:  2001-08       Impact factor: 2.565

5.  Survivin expression in human osteosarcoma is a marker for survival.

Authors:  K Trieb; R Lehner; T Stulnig; I Sulzbacher; K R Shroyer
Journal:  Eur J Surg Oncol       Date:  2003-05       Impact factor: 4.424

6.  C-reactive protein, erythrocyte sedimentation rate and orthopedic implant infection.

Authors:  Kerryl E Piper; Marta Fernandez-Sampedro; Kathryn E Steckelberg; Jayawant N Mandrekar; Melissa J Karau; James M Steckelberg; Elie F Berbari; Douglas R Osmon; Arlen D Hanssen; David G Lewallen; Robert H Cofield; John W Sperling; Joaquin Sanchez-Sotelo; Paul M Huddleston; Mark B Dekutoski; Michael Yaszemski; Bradford Currier; Robin Patel
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

Review 7.  C-reactive protein: risk marker or mediator in atherothrombosis?

Authors:  Ishwarlal Jialal; Sridevi Devaraj; Senthil K Venugopal
Journal:  Hypertension       Date:  2004-05-17       Impact factor: 10.190

Review 8.  Prognostic factors in osteosarcoma: a critical review.

Authors:  A M Davis; R S Bell; P J Goodwin
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

Review 9.  C-reactive protein: the best laboratory indicator available for monitoring disease activity.

Authors:  S D Deodhar
Journal:  Cleve Clin J Med       Date:  1989 Mar-Apr       Impact factor: 2.321

10.  Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy.

Authors:  K Trieb; R Gerth; G Holzer; J G Grohs; P Berger; R Kotz
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

View more
  17 in total

1.  Tumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcome.

Authors:  Christoph J Laux; Gundula Berzaczy; Michael Weber; Susanna Lang; Martin Dominkus; Reinhard Windhager; Iris-Melanie Nöbauer-Huhmann; Philipp T Funovics
Journal:  Int Orthop       Date:  2014-11-30       Impact factor: 3.075

2.  Novel classifiers with clinical laboratory parameters for early detection of osteosarcoma.

Authors:  Lin-Lin Cao; Zhaoming Chen; Zhihong Yue; Lin Pei; Mei Jia; Hui Wang; Tingting Li
Journal:  J Clin Lab Anal       Date:  2020-01-08       Impact factor: 2.352

3.  Impact of close surgical margin on local recurrence and survival in osteosarcoma.

Authors:  Xin Li; Vincent M Moretti; Adedayo O Ashana; Richard D Lackman
Journal:  Int Orthop       Date:  2011-03-15       Impact factor: 3.075

4.  Serum C-reactive protein and overall survival of patients with osteosarcoma.

Authors:  Xiaochuan Li; Feng Tian; Fei Wang; Yanfeng Li
Journal:  Tumour Biol       Date:  2015-05-19

5.  Glasgow prognostic score is an independent marker for poor prognosis with all cases of epithelial ovarian cancer.

Authors:  Chiaki Omichi; Keiichiro Nakamura; Junko Haraga; Hisashi Masuyama; Yuji Hiramatsu
Journal:  Cancer Med       Date:  2016-03-01       Impact factor: 4.452

6.  Prognostic value of inflammation-based scores in patients with osteosarcoma.

Authors:  Bangjian Liu; Yujing Huang; Yuanjue Sun; Jianjun Zhang; Yang Yao; Zan Shen; Dongxi Xiang; Aina He
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

7.  The role of CRP and ATG9B expression in clear cell renal cell carcinoma.

Authors:  Zheng Ma; Zengguang Qi; Zhengfei Shan; Jiangsong Li; Jing Yang; Zhonghua Xu
Journal:  Biosci Rep       Date:  2017-11-15       Impact factor: 3.840

Review 8.  C-reactive protein as a prognostic factor for human osteosarcoma: a meta-analysis and literature review.

Authors:  Jian-Hua Yi; Dong Wang; Zhi-Yong Li; Jun Hu; Xiao-Feng Niu; Xiao-Lin Liu
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

9.  C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum--a single center pilot study.

Authors:  Gerhard Martin Hobusch; Florian Bodner; Sonja Walzer; Rodrig Marculescu; Philipp T Funovics; Irene Sulzbacher; Reinhard Windhager; Joannis Panotopoulos
Journal:  World J Surg Oncol       Date:  2016-04-18       Impact factor: 2.754

10.  The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma.

Authors:  Ninna Aggerholm-Pedersen; Katja Maretty-Kongstad; Johnny Keller; Steen Baerentzen; Akmal Safwat
Journal:  Transl Oncol       Date:  2016-08       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.